Antipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients
|
|
|
- Shonda Anastasia Roberts
- 6 years ago
- Views:
Transcription
1 Antipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients Preferred Agents (Oral) a Amitriptyline/Perphenazine (Generic) Aripiprazole Tablet (Generic) b Chlorpromazine Tablet (Generic) Clozapine Tablet (Generic) b Fluphenazine Tablet (Generic) Haloperidol Oral Tablet (Generic) Haloperidol Lactate Concentrate (Generic) Loxapine Capsule (Generic) Olanzapine Tablet, ODT (Generic) b Perphenazine Tablet (Generic) Pimozide Tablet (Orap ) Quetiapine Tablet (Generic) b Quetiapine ER Tablet (Seroquel XR ) Risperidone Solution, Tablet (Generic) b Thioridazine Tablet (Generic) Thiothixene Capsule (Generic) Trifluoperazine Tablet (Generic) Ziprasidone Capsule (Generic) b Non-Preferred Agents (Oral) a Aripiprazole Tablet (Abilify ) b Aripiprazole ODT (Generic) b Aripiprazole Oral Solution (Generic; Abilify ) b Asenapine Sublingual Tablet (Saphris ) b Brexpiprazole Tablet (Rexulti ) b Cariprazine Capsule (Vraylar ) b Clozapine Tablet (Clozaril ) b Clozapine Suspension (Versacloz ) b Clozapine ODT (Generic; Authorized Generic; FazaClo ) b Fluphenazine Elixir/Solution (Generic) Iloperidone Tablet (Fanapt ) b Loxapine Inhalation (Adasuve ) Lurasidone Tablet (Latuda ) b Molindone Tablet (Generic) Olanzapine Tablet, ODT (Zyprexa ; Zyprexa Zydis ) b Olanzapine/Fluoxetine (Generic; Symbyax ) b Paliperidone ER Tablet (Authorized Generic; Generic; Invega ) b Pimavanserin Tablet (Nuplazid ) Pimozide Tablet (Generic) Quetiapine Tablet (Seroquel ) b Risperidone ODT (Generic; Risperdal M-Tab ) b Risperidone Solution, Tablet (Risperdal ) b Ziprasidone Capsule (Geodon ) b Preferred Agents (Injection) a Aripiprazole Lauroxil Intramuscular (Aristada ) b,c,d Aripiprazole Intramuscular ER (Abilify Maintena ) d Fluphenazine Decanoate Injection d (Generic) Haloperidol Decanoate Injection d (Generic) Haloperidol Lactate Injection (Generic) Paliperidone Intramuscular (Invega Sustenna d ; Invega Trinza b,c,d,e ) Risperidone (Risperdal Consta ) d Ziprasidone Intramuscular (Geodon ) a Diagnosis code requirements apply to both preferred and non-preferred agents. (See Table 1) b Maximum daily dose edits may apply to both preferred and non-preferred agents. (See Table 2) c Quantity limits may apply to both preferred and non-preferred agents. (See Table 3) d Established tolerance with oral formulation (paid claim for oral formulation) OR established therapy with requested injectable (paid claim for requested injectable) required within the previous 60-day period. e Previous use of Invega Sustenna is required. Non-Preferred Not Reviewed Quetiapine ER Tablet (Authorized Generic of Seroquel XR ) Quetiapine ER Tablet (Seroquel XR Sample Kit) Non-Preferred Agents (Injection) a Haloperidol Decanoate (Haldol ) d Haloperidol Lactate (Haldol ) Olanzapine Intramuscular Solution (Generic; Zyprexa ) Olanzapine Intramuscular Suspension (Zyprexa Relprevv ) d Page 1 of 6
2 To request prior authorization, quantity limit override, or maximum daily dose override: for recipients under 18 years of age - use the LA Medicaid FFS/MCO Behavioral Medication Therapy Prior Authorization Form; for recipients 18 years of age and older, use the Healthy Louisiana Prior Authorization Form. Approval Criteria for ALL Agents (Preferred and Non-Preferred) for Recipients Under 6 Years of Age: The recipient has at least ONE of the approved diagnoses. (See Table 1); AND, For a non-preferred agent, one of the following conditions apply: o The recipient has had treatment failure with at least one preferred product; OR o The recipient has had an intolerable side effect to at least one preferred product; OR o The recipient has a documented contraindication to all of the preferred products which are appropriate for the condition being treated; OR o There is no preferred product appropriate to use for the condition being treated; OR o The recipient is established on the medication with positive clinical outcomes; AND The prescriber attests that a systematic evaluation and assessment have been performed which includes but is not limited to, the following: o Detailed history of symptoms (including symptoms from non-custodial caregivers); AND o Medical, substance use, developmental, and social factors that may influence clinical presentation have been addressed AND o Documentation of in-office observations (including appointment dates) which support recorded behavior / symptoms; AND o Documentation of impairing, extreme symptoms of aggression towards self and/or others; AND Documentation of baseline and ongoing clinical monitoring must be provided, which includes ALL of the following: o FBS or HbA1C o Lipid panel o Prolactin level o Weight and height or BMI percentile o Extrapyramidal symptoms using the Abnormal Involuntary Movement Scale (AIMS) Approval Criteria for Non-Preferred Agents for Recipients Greater than or Equal to 6 years of Age: The recipient has at least ONE of the approved diagnoses. (See Table 1); AND For a non-preferred agent, one of the following conditions apply: o The recipient has had treatment failure with at least one preferred product; OR o The recipient has had an intolerable side effect to at least one preferred product; OR o The recipient has a documented contraindication to all of the preferred products which are appropriate for the condition being treated; OR o There is no preferred product appropriate to use for the condition being treated; OR o The recipient is established on the medication with positive clinical outcomes; AND Documentation of baseline and ongoing clinical monitoring must be provided for all recipients under 18 years of age, which includes ALL of the following: o FBS or HbA1C o Lipid panel o Prolactin level o Weight and height or BMI percentile o Extrapyramidal symptoms using the Abnormal Involuntary Movement Scale (AIMS) Duration of Prior Authorization Approval: Initial Approval: 12 months Reauthorization Approval: 12 months Page 2 of 6
3 Approval criteria for all ages to override maximum daily dose and/or quantity limits: Clear evidence of the diagnosis is required along with ONE of the following: The recipient has been treated in the past or is currently receiving treatment with the requested dosage and quantity of the requested medication with a lack of objective adverse effects (such as weight) and subjective adverse effects (by patient report); OR The recipient had a partial but inadequate response to the requested medication at a lower dosage/quantity available under the plan AND ALL of the following: o Medication non-adherence was ruled out as a reason for the inadequate response; AND o The recipient tolerated the medication at the lower dosage; AND o There was a lack of objective adverse effects (such as weight) and subjective adverse effects (by patient report) o The requested dose is considered medically necessary; OR The recipient has not previously used this medication; however, the prescriber is submitting evidence supporting quantity limit exception with this request (for example, a peer-reviewed journal article demonstrating the safety and efficacy of the requested dose for the indication); AND ALL of the following: o The requested quantity and dosing is supported in the accepted medical compendia; AND o The requested dose is considered medically necessary Page 3 of 6
4 Table 1. Approved ICD-10-CM Diagnosis Codes for Antipsychotic Medications Generic - Brand Examples Diagnosis Description ICD-10 Codes Aripiprazole Oral - Abilify Aripiprazole Injection Suspension - Abilify Maintena Injection Aripiprazole Lauroxil ER Injection Suspension - Aristada Injection Asenapine - Saphris Brexpiprazole - Rexulti Cariprazine - Vraylar Chlorpromazine Oral, Injection Clozapine - Clozaril, FazaClo, Versacloz Fluphenazine Oral, Injection, Decanoate Injection Haloperidol Oral, Decanoate and Lactate Injection - Haldol Iloperidone - Fanapt Loxapine, Breath Activated Aerosol Powder - Adasuve Loxapine, Capsule Lurasidone - Latuda Olanzapine Oral and Injection - Zyprexa Olanzapine Injection Suspension - Zyprexa Relprevv Paliperidone Oral - Invega Paliperidone Injection (1-month) - Invega Sustenna Paliperidone Injection (3-month) - Invega Trinza Perphenazine Prochlorperazine Oral and Injection - Compazine Quetiapine - Seroquel Quetiapine XR - Seroquel XR Risperidone Oral - Risperdal Risperidone Injection Suspension - Risperdal Consta Thioridazine Thiothixene Trifluoperazine Ziprasidone Oral and Injection - Geodon Olanzapine/Fluoxetine - Symbyax Perphenazine/Amitriptyline Agitation or Aggression or Irritability in Pervasive Developmental Disorder (PDD)/Autistic Disorder Negative Symptoms of Pervasive Developmental Disorder (PDD) Aggression or Irritability in Pervasive Developmental Disorder (PDD) with Depression Bipolar Disorder, Agitation or Psychoses in Bipolar Disorder, Agitation or Psychoses in Other Episodic Mood Disorders Bipolar Depression, Negative Symptoms of Psychoses in Bipolar Disorder, Negative Symptoms of Psychoses in Other Episodic Mood Disorders Bipolar Disorder with Depression, Other Episodic Mood Disorders with Depression Delusions, Dementia, Psychoses or Agitation in Delusions, Dementia, Psychoses Negative Symptoms of Delusions, Dementia or Psychoses Delusions with Depression, Dementia with Depression, Psychoses with Depression Agitation or Psychoses in Major Depressive Disorder Major Depressive Disorder, Negative Symptoms of Psychoses in Major Depressive Disorder Major Depressive Disorder Schizophrenia or Schizoaffective Disorder or Agitation in Schizophrenia or Schizoaffective Disorder Negative Symptoms of Schizophrenia or Schizoaffective Disorder Schizophrenia with Depression, Schizoaffective Disorder with Depression F84.* F30.*, F31.*, F32.8, F34.8, F34.9, F39 F01.*, F02.*, F03.*, F04, F05, F06.0, F06.2, F06.30, F06.31, F06.32, F06.33, F06.34, F06.8, F10.150, F10.151, F10.250, F10.251, F10.26, F10.94, F10.950, F10.951, F10.96, F10.97, F11.121, F11.150, F11.151, F11.221, F11.250, F11.251, F11.921, F11.950, F11.951, F12.121, F12.150, F12.151, F12.221, F12.250, F12.251, F12.921, F12.950, F12.951, F13.121, F13.150, F13.151, F13.221, F13.250, F13.251, F13.27, F13.921, F13.950, F13.951, F13.97, F14.121, F14.150, F14.151, F14.221, F14.250, F14.251, F14.921, F14.950, F14.951, F15.121, F15.150, F15.151, F15.221, F15.250, F15.251, F15.921, F15.950, F15.951, F16.121, F16.150, F16.151, F16.221, F16.250, F16.251, F16.921, F16.950, F16.951, F18.121, F18.150, F18.151, F18.17, F18.221, F18.250, F18.251, F18.27, F18.921, F18.950, F18.951, F18.97, F19.121, F19.150, F19.151, F19.17, F19.221, F19.250, F19.251, F19.27, F19.921, F19.950, F19.951, F19.97, F22, F23, F24, F28, F29, F32.3, F33.3, F44.89 F32.0, F32.1, F32.2, F32.3, F32.4, F32.5, F32.9, F33.0, F33.1, F33.2, F33.3, F33.40, F33.41, F33.42, F33.8, F33.9 F20.*, F25.* Page 4 of 6
5 Table 1. Approved ICD-10-CM Diagnosis Codes for Antipsychotic Medications (continued) Generic - Brand Examples Diagnosis Description ICD-10 Codes Aripiprazole Oral - Abilify Olanzapine Oral - Zyprexa Quetiapine - Seroquel Quetiapine XR - Seroquel XR Risperidone Oral - Risperdal Ziprasidone Oral - Geodon Aggression in Conduct Disorder, Disruptive Behavior Disorder, Explosive Personality Disorder, Impulse Control Disorder, Intermittent Explosive Disorder, Isolated Explosive Disorder, Pervasive Developmental Disorder, or Unsocialized Aggression Aripiprazole Oral - Abilify Haloperidol Oral and Lactate Injection - Haldol Pimozide - Orap Quetiapine - Seroquel Quetiapine XR - Seroquel XR Risperidone Oral - Risperdal Risperidone Injection Suspension - Risperdal Consta Additional Covered Codes: Borderline Personality Disorder, Depersonalization Disorder, Obsessive-Compulsive Disorder, Paranoid Personality Disorder Tics/Tourette s Disorder F60.3, F63.3, F63.8*, F63.9, F84.*, F91.1, F91.8, F91.9 F42, F48.1, F60.0, F60.3 F95.*, G25.6* Chlorpromazine Oral, Injection Chlorpromazine Oral and Injection Haloperidol Oral - Haldol Perphenazine Prochlorperazine Oral, Injection and Rectal - Compazine Hiccough R06.6 Nausea and Vomiting G43.A0, K91.0, R11.* Porphyria E80.0, E80.1, E80.20, E80.21, E80.29 Tetanus A35 Hyperkinetic Syndrome F90.* Severe Behavioral Problems F43.24, F63.81, F91.1, F91.8, F91.9 Severe Nausea and Vomiting G43.A0, K91.0, R11.* Olanzapine/Fluoxetine - Symbyax Perphenazine/Amitriptyline Depression F31.3*, F31.4, F31.5, F31.7/5, F31.76, F31.81, F31.9, F32.*, F33.*, F34.1 Perphenazine/Amitriptyline Prochlorperazine Oral - Compazine Trifluoperazine Anxiety F06.4, F34.1, F41.* * Any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM diagnosis code Diagnosis description is specific for olanzapine/fluoxetine (Symbyax ). Diagnosis description is specific for perphenazine/amitriptyline. Diagnosis description is specific for aripiprazole oral (Abilify ), brexpiprazole (Rexulti ), and quetiapine XR (Seroquel XR ). Please note: if recipient s diagnosis code is not included in this list, the prescribing provider may call the appropriate MCO / FFS plan for guidance. Page 5 of 6
6 Table 2. Maximum Daily Dose for Selected Agents by Age* Age (Years) Generic Brand Example Younger and older than 5 Aripiprazole Abilify 5mg 20mg 20mg 20mg 30mg 30mg 30mg Aripiprazole Aristada 0mg 0mg 0mg 0mg 0mg 0mg 1064mg Asenapine Saphris 0mg 0mg 0mg 20mg 20mg 20mg 20mg Brexpiprazole Rexulti 0mg 0mg 0mg 0mg 0mg 4mg 4mg Cariprazine Vraylar & Vraylar Therapy Pack 0mg 0mg 0mg 0mg 0mg 0mg only emergency override available for pack 4.5mg 6mg Clozapine Clozaril, FazaClo, Versacloz 0mg 0mg 0mg 0mg 0mg 0mg 900mg Iloperidone Fanapt 0mg 0mg 0mg 0mg 0mg 16mg 24mg Lurasidone Latuda 0mg 0mg 0mg 0mg 80mg 80mg 160mg Olanzapine Zyprexa 10mg 20mg 20mg 20mg 30mg 30mg 40mg Olanzapine/Fluoxetine Symbyax *Prior authorization is required to exceed these maximum daily doses. Table 3. Quantity Limits for Selected Agents* Medication Aristada 441mg syringe Aristada 662mg syringe Aristada 882mg syringe Aristada 1064mg syringe Invega Trinza Vraylar Therapy Pack 0mg 0mg 0mg *Prior authorization is required to exceed these quantity limits. 12mg/ 50mg 12mg/ 50mg 12mg/ 50mg Quantity Limit 1 unit every 28 days 1 unit every 28 days 1 unit every 28 days 1 unit every 56 days 1 kit per rolling 90 days Limited to 1 pack per 18 month period 18mg/ 75mg Paliperidone Invega 3mg 6mg 6mg 6mg 9mg 9mg 12mg Paliperidone Invega Trinza 0mg 0mg 0mg 0mg 0mg 0mg 819mg Quetiapine Seroquel 100mg 600mg 600mg 600mg 1000mg 1000mg 1200mg Risperidone Risperdal 3mg 6mg 6mg 6mg 8mg 8mg 16mg Ziprasidone Geodon 30mg 60mg 60mg 60mg 120mg 120mg 200mg Page 6 of 6
Antipsychotic Medications Age and Step Therapy
Market DC *- Florida Healthy Kids Antipsychotic Medications Age and Step Therapy Override(s) Approval Duration Prior Authorization 1 year Quantity Limit *Virginia Medicaid See State Specific Mandates *Indiana
Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria
Drug/Drug Class Antipsychotics Clinical Criteria Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria Prior
Pharmacy Benefit Management (PBM) Program FORMULARY/PRODUCT RESTRICTIONS
Workforce Safety & Insurance Revised Document Date: 07/21/2015 1600 E Century Ave Ste 1 PO Box 5585 Bismarck, ND 58506-5585 701.328.3800 1.800.777.5033 www.workforcesafety.com Pharmacy Benefit Management
Pharmacy Medical Necessity Guidelines: Antipsychotic Medications
Pharmacy Medical Necessity Guidelines: Effective: October 1, 2016 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
Step Therapy Group. Atypical Antipsychotic Agents
Atypical Antipsychotic Agents Any beneficiary newly enrolled into Community Care, Inc. currently receiving aripiprazole, aripiprazole ODT, risperidone, risperidone ODT, olanzapine, olanzapine ODT, quetiapine,
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Invega Sustenna, Invega Trinza) Reference Number: CP.PHAR.291 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Medicaid See Important Reminder at the end of this policy
Pharmacy Medical Necessity Guidelines: Antipsychotic Medications
Pharmacy Medical Necessity Guidelines: Effective: April 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Abilify Maintena, Aristada, Aristada Initio) Reference Number: CP.PHAR.290 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Medicaid Coding Implications Revision Log
Texas Standard Prior Authorization Form Addendum
Texas Standard Prior Authorization Form Addendum Molina Healthcare of Texas Antipsychotics (Medicaid) This fax machine is located in a secure location as required by HIPAA Regulations. Complete / Review
HOSPITAL BASED INPATIENT PSYCHIATRIC SERVICES (HBIPS) MEASURE SET
HOSPITAL BASED INPATIENT PSYCHIATRIC SERVICES (HBIPS) MEASURE SET Kathy Wonderly RN, MSEd, CPHQ Consultant Developed: February, 2013 Most recently revised: December 2018 The Psychiatric Measure Set CMS
Clinical Policy: Olanzapine Long-Acting Injection (Zyprexa Relprevv) Reference Number: CP.PHAR.292 Effective Date: Last Review Date: 08.
Clinical Policy: (Zyprexa Relprevv) Reference Number: CP.PHAR.292 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Medicaid See Important Reminder at the end of this policy for important
Texas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
Pharmacy Medical Necessity Guidelines: Antipsychotic Medications
Pharmacy Medical Necessity Guidelines: Antipsychotic Medications Effective: July. 1, 2016 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy
Literature Scan: Parenteral Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
ABILIFY INJ. Products Affected Step 2: ABILIFY MAINTENA PREFILLED SYRINGE 300 MG INTRAMUSCULAR ABILIFY MAINTENA PREFILLED SYRINGE 400 MG INTRAMUSCULAR
ABILIFY INJ ABILIFY MAINTENA PREFILLED SYRINGE 300 MG ABILIFY MAINTENA PREFILLED SYRINGE 400 MG ABILIFY MAINTENA SUSPENSION RECONSTITUTED ER 300 MG Claim will pay automatically for ABILIFY MAINTENA if
Rexulti (brexpiprazole)
Market DC Rexulti (brexpiprazole) Override(s) Approval Duration Prior Authorization 1 year Quantity Limit *Indiana see State Specific Mandates below *Maryland see State Specific Mandates below *Virginia
Commissioner for the Department for Medicaid Services Selections for Preferred Products
Commissioner for the Department for Medicaid Services Selections for Preferred Products This is a summary of the final Preferred Drug List (PDL) selections made by the Commissioner for the Department for
MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Antipsychotics
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Antipsychotics A. Prescriptions That Require Prior Authorization Prescriptions for Antipsychotics
Nebraska Medicaid Criteria. Abilify Maintena
Nebraska Medicaid Criteria All initial and renewal authorizations are for 12 months in duration. Abilify Maintena *Criteria for Authorization for Abilify Maintena The individual has a current DSM diagnosis
Slide 1. Slide 2. Slide 3. About this module. About this module. Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics
Slide 1 Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics Flavio Guzmán, MD Slide 2 About this module 13 antipsychotics will be studied 3 first generation antipsychotics 10 second
Judges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children
Judges Reference Table for the Psychotropic Medication Utilization Parameters for Foster Children Stimulants for treatment of ADHD Preschool (Ages 3-5 years) Child (Ages 6-12 years) Adolescent (Ages 13-17
What Team Members Other Than Prescribers Need To Know About Antipsychotics
What Team Members Other Than Prescribers Need To Know About Antipsychotics The Care Transitions Network National Council for Behavioral Health Montefiore Medical Center Northwell Health New York State
Drug Class Literature Scan: Oral and Parenteral Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-2596
Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety
Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
Antipsychotics and stroke risk
Integrating Sentinel into Routine Regulatory Drug Review: A Snapshot of the First Year Antipsychotics and stroke risk Lockwood G. Taylor, PhD, MPH Division of Epidemiology II Office of Pharmacovigilance
REXULTI (brexpiprazole) oral tablet
REXULTI (brexpiprazole) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
A Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer
A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.
Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety
Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety 2017 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE
STEP THERAPY CRITERIA
DRUG CLASS PRODUCTS) BRAND NAME (BRAND ONLY) (generic) STEP THERAPY CRITERIA ATYPICAL ANTIPSYCHOTICS (BRAND ONLY ABILIFY (AL TABLET & AL SOLUTION ONLY) (aripiprazole) FANAPT (BRAND ONLY) (iloperidone)
Drug Use Criteria: Atypical Antipsychotics (oral)
Texas Vendor Drug Program Drug Use Criteria: Atypical Antipsychotics (oral) Publication History 1. Developed: February 1997 2. Revised: September 2017; September 2015; December 2013; February 2012; June
Antipsychotics. Something Old, Something New, Something Used to Treat the Blues
Antipsychotics Something Old, Something New, Something Used to Treat the Blues Objectives To provide an overview of the key differences between first and second generation agents To an overview the newer
Pharmacy Medical Necessity Guidelines: Atypical Antipsychotic Medications. Effective: February 20, 2017
Pharmacy Medical Necessity Guidelines: Effective: February 20, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)
Pharmacy Medical Necessity Guidelines: Atypical Antipsychotic Medications. Effective: December 12, 2017
Pharmacy Medical Necessity Guidelines: Effective: December 12, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)
Kelly E. Williams, Pharm.D. PGY2 Psychiatric Pharmacy Resident April 16,2009
Kelly E. Williams, Pharm.D. PGY2 Psychiatric Pharmacy Resident April 16,2009 List the antipsychotics most often prescribed Compare and contrast the use and adverse effects experienced in the pediatric
Michael J. Bailey, M.D. OptumHealth Public Sector
Michael J. Bailey, M.D. OptumHealth Public Sector LIHP Quality Charter To ensure the quality of care delivered to enrollees in San Diego County Assistance Programs, such as County Medical Services (CMS)
10/2/2017. Evaluate existing data in regards to the appropriate treatment of schizophrenia
Evaluate existing data in regards to the appropriate treatment of schizophrenia Review risks and benefits of antipsychotic therapy in the management of acute psychosis Rebecca L. Jones, Pharm.D., B.C.P.P.
Proposed Changes to Existing Measure for HEDIS : Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)
Proposed Changes to Existing Measure for HEDIS 1 2020: Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA) NCQA seeks comments on proposed modifications to the HEDIS Health
Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist. HMS Training Webinar January 27, 2017
Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist HMS Training Webinar January 27, 2017 1 Describe nationwide prevalence and types of elderly dementia + define BPSD Define psychotropic
Molina Healthcare of Texas
Texas Standard Prior Authorization Form Addendum Molina Healthcare of Texas Ingrezza (Marketplace) This fax machine is located in a secure location as required by HIPAA Regulations. Complete / Review information,
Objectives. Antipsychotics 7/25/2016. LeadingAge Florida 53rd Annual Convention & Exposition
Reducing the Use of Antipsychotics in Long Term Care Communities Alan W. Obringer RPh, CPh, CGP Executive Director Senior Care Pharmacy Objectives Recognize the clinical evidence for the need to change
Antipsychotic Prior Authorization Request
Antipsychotic Prior Authorization Request Commonwealth of Massachusetts MassHealth Drug Utilization Review Program P.O. Box 2586, Worcester, MA 01613-2586 Fax: 1-877-208-7428 Phone: 1-800-745-7318 MassHealth
Comparison of Atypical Antipsychotics
PL Detail-Document #281006 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER October 2012 Comparison of
ANTIPSYCHOTICS/ NEUROLEPTICS
Pharmacological Interventions Tutorial Antipsychotic medications First Generation (Typicals) Includes phenothiazines, thioxanthenes, butyrophenones ANTIPSYCHOTICS/ NEUROLEPTICS Second Generation (Atypicals)
Riding the Waves: Tools for the Management of Bipolar Disorder
Riding the Waves: Tools for the Management of Bipolar Disorder Jacintha S. Cauffield, Pharm.D., BCPS, CDE Associate Professor of Pharmacy Practice Palm Beach Atlantic University Lloyd L. Gregory School
Medications and Children Disorders
Mental Health Comprehensive Services Providing Family Stability and Developing Life Coping Skills Medications and Children Disorders Psychiatric medications can be an effective part of the treatment for
COVERED SERVICES, LIMITATIONS AND EXCLUSIONS
COVERED SERVICES, LIMITATIONS AND EXCLUSIONS This section provides the terms and conditions under which prescription services will be paid by the Medicaid Program and a description of the authorized benefits
IOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road (515)
IOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road (515) 974-3131 -866-626-0216 Brett Faine, Pharm.D. Larry Ambroson, R.Ph. Casey Clor, M.D. Professional Staff: Mark Graber, M.D., FACEP
Treat Schizophrenia Schizoaffective disorder Bipolar disorder Psychotic depression Off-label uses Insomnia Tics Delirium Stuttering
Robert M. Millay RN MSN Ed Professor, Napa Valley College Psychiatric Technician Programs Copyright 2015, 2011, 2007, 2003, 1999, 1995, 1991 by Mosby, an imprint of Elsevier Inc. Treat Schizophrenia Schizoaffective
2017 HEDIS Pediatric Toolkit
2017 HEDIS Pediatric Toolkit Prepared By: Quality Improvement Department, Molina Healthcare of Washington MolinaHealthcare.com HEDIS 2017 TABLE OF CONTENTS Welcome to 2017 HEDIS TIPS...2 Molina Provider
First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness
1 First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness This continuing education monograph examines the results of a comparative effectiveness review to compare
NEWER ATYPICAL ANTIPSYCHOTICS: NOVEL IDEAS OR
NEWER ATYPICAL ANTIPSYCHOTICS: NOVEL IDEAS OR METOOS? Sanaz Farhadian, Pharm.D., BCPP Clinical Psychiatric Pharmacist Veterans Affairs Healthcare System, San Diego, CA OBJECTIVES Discuss new antipsychotics
Class Update: Oral Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
INJECTABLE ANTIPSYCHOTICS AUTHORIZATION FORM
SUBMIT TO Utilization Management Department Phone: 1.866.912.6285 Fax: 1.866.694.3649 MEMBER INFORMATION INJECTABLE ANTIPSYCHOTICS AUTHORIZATION FORM Fax completed form to Cepatico at 866.694.3649. Upon
Antipsychotic Medication
Antipsychotic Medication Mary Knutson, RN 3-7-12 Mosby items and derived items 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 1 Clinical Uses of Antipsychotics Short-term: in severe depression and
Appendix: Psychotropic Medication Reference Tables
Appendix: Psychotropic Medication Reference Tables How to Use these Tables These reference tables are designed to provide clinic staff with specific medication related criteria for the Polypharmacy, Cardiometabolic
HEDIS BEHAVIORAL HEALTH RESOURCE GUIDE
HEDIS BEHAVIORAL HEALTH RESOURCE GUIDE What is HEDIS? 3 HEDIS Reference Guide for Behavioral Health 4 Behavioral Health HEDIS Measures 13 WHAT IS HEDIS? HEDIS (Healthcare Effectiveness Data and Information
U T I L I Z A T I O N E D I T S
I N D I A N A H E A L T H C O V E R A G E P R O G R A M S U T I L I Z A T I O N E D I T S A P R I L 1 9, 2 0 1 2 s for s Refer to Provider Bulletin BT200709 for additional information regarding the Mental
Implementation of Performance Improvement Projects
Implementation of Performance Improvement Projects Mary Marlatt-Dumas, Quality Manager, NMRE, Region 2 Diane L. Bennett, QI Coordinator/Compliance Officer, NorthCare Network, Region 1 Bill Phelps, Quality
Table of Contents Introduction... 3
Table of Contents Introduction... 3 Diabetes Care Overview - General HEDIS Tips to Improve Scores... 4 HEDIS Tip Sheets... 5 Comprehensive Diabetes Care Medical Record Documentation... 6 Comprehensive
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: AZ.CP.PHAR.10.11.10 Effective Date: 07.16 Last Review Date: 09.12.18 Line of Business: Medicaid Arizona Revision Log See Important Reminder at the end of this policy
This factsheet covers:
Antipsychotics If you experience psychosis as part of your illness, you may be offered antipsychotic medication. Antipsychotics are generally used to treat psychosis, but are also used to treat bipolar
2019 STEP THERAPY CRITERIA UCare Individual & Family Plans UCare Individual & Family Plans with Fairview
2019 STEP THERAPY CRITERIA UCare Individual & Family Plans UCare Individual & Family Plans with Fairview In some cases, UCare requires you to first try certain drugs to treat your medical condition before
Table of Contents Introduction... 3
Table of Contents Introduction... 3 Diabetes Care Overview - General HEDIS Tips to Improve Scores... 4 HEDIS Tip Sheets... 5 Comprehensive Diabetes Care Medical Record Documentation... 6 Comprehensive
Psychopharmacologic Updates. Nimisha Gokaldas, MD Medical Director Multnomah County, Mental Health and Addiction Services Division
Psychopharmacologic Updates Nimisha Gokaldas, MD Medical Director Multnomah County, Mental Health and Addiction Services Division This author has NO affiliations with or involvement in any organization
LATUDA Commercial Update
LATUDA Commercial Update LATUDA Meeting (Tokyo) January 2011 Mark Iwicki President and Chief Operating Officer Sunovion Pharmaceuticals Inc. Sunovion Is Uniquely Positioned to Deliver Strong Performance
How did we get here? 1876 Methylene Blue. Insecticide 1935 Du Pont Anthelmintic. Garrett McCann, RPh
Polypharmacy, Adverse Effects, and the Importance of Tapering Medications for People with Intellectual and Developmental Disabilities Garrett McCann, RPh How did we get here? 1876 Methylene Blue Insecticide
Drug Class Review Second Generation Antipsychotic Drugs
Drug Class Review Second Generation Antipsychotic Drugs Final Update 4 Report November 2013 The purpose of reports is to make available information regarding the comparative clinical effectiveness and
Nuplazid (pimavanserin)
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class This criteria was recommended for review by the Texas Medicaid Vendor Drug Program to ensure appropriate and safe utilization. Additional
Quarterly Pharmacy Formulary Change Notice
MEDICAID PROVIDER BULLETIN February 26, 2015 Quarterly Pharmacy Formulary Change Notice Summary of Change: The formulary changes listed in the table below were reviewed and approved at our September 24,
CONTRAINDICATIONS TABLE
CONTRAINDICATIONS TABLE Generic Name Brand Name Contraindications Amphetamine Salts Adderall, Adderall XR Hypersensitivity to amphetamine, dextroamphetamine, or other sympathomimetic amines Advanced arteriosclerosis
ANTIDEPRESSANTS. Details. Step Therapy 2017 Last Updated: 5/23/2017
ANTIDEPRESSANTS EMSAM PATCH 24 HOUR 12 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 6 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 9 MG/24HR TRANSDERMAL FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG FETZIMA CAPSULE
Schizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM
Schizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM NURS 203 GENERAL PHARMACOLOGY DANITA NARCISO PHARM D Learning Objectives Understand the result of dopamine binding to D2 receptors
Current Non-Preferred Agents
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
Antipsychotics. This factsheet covers -
Antipsychotics If you experience psychosis as part of an illness, you may be offered antipsychotic medication. Antipsychotics are generally used to treat psychosis, but are also used to treat bipolar disorder
Plante Moran Clinical Group
Handouts Prepared By: Jane Belt, MS, RN, RAC-MT Plante Moran Clinical Group jane.belt@ 2 Plante Moran Clinical Group 2013 1 Objectives Delineate the key requirements in F329 Unnecessary Medications Describe
Indiana Medicaid Drug Utilization Review Board Newsletter
Indiana Medicaid Drug Utilization Review Board Newsletter Volume 15 Issue 1 April 2012 Indiana Medicaid DUR Board Room W382 Indiana State Government Center, South 402 West Washington Street Indianapolis,
Antipsychotics in Bipolar
Use of Second-Generation Antipsychotics in Bipolar Disorder: A Practical Guide Flavio Guzman, MD Editor Psychopharmacology Institute This practical guide is an update on the use of second-generation antipsychotics
New Drug Evaluation: pimavanserin tablet, oral
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
Abbreviated Class Review: Long-Acting Injectable Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
Abbreviated Class Review: Long-Acting Injectable Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
Schedule FDA & literature based indications
Psychotropic Medication List Recommended dosages are intended to serve only as a guide for children. Recommended doses are literature based. Clinicians should consult package insert of medications for
PPHP 2017 Formulary 2017 Step Therapy Criteria
ARISTADA Aristada Prefilled Syringe 1064 MG/3.9ML Intramuscular Aristada Prefilled Syringe 441 MG/1.6ML Intramuscular Aristada Prefilled Syringe 662 MG/2.4ML Intramuscular Aristada Prefilled Syringe 882
Regier 1993; Kessler 2005; Stevens 2016; Parellada 206; Mohr 2012; Prajapati 2016;
Regier 1993; Kessler 2005; Stevens 2016; Parellada 206; Mohr 2012; Prajapati 2016; Miyamoto 2017 Risperdal Consta (risperidone) Zyprexa Relprevv (olanzapine pamoate) Invega Sustenna (paliperidone palmiate)
DSM-5 Criteria: Schizophrenia
DSM-5 Criteria: Schizophrenia Box 4. DSM-5 Diagnosis: Schizophrenia Two (or more) of the following, each present for a significant portion of time during a 1-month period (or less if successfully treated).
Supplementary Online Content
Supplementary Online Content Huybrechts KF, Hernández-Díaz S, Patorno E, et al. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatry. Published online August 17, 2016.
MO Medicaid Foster Care Drugs FY10-FY14
MO Medicaid Foster Care Drugs FY10-FY14 Medicaid (MO HealthNet) Cost of Drugs given to Missouri Foster Care Children by combinations of Age, Gender, Drug Class and Fiscal Year [Raw Data Provided by Missouri
Psychotropics and Foster Care: Challenge or Opportunity?
Psychotropics and Foster Care: Challenge or Opportunity? Raymond C. Love, PharmD, BCPP, FASHP Professor and Director, Mental Health Program University of Maryland School of Pharmacy Objectives At the conclusion
Attention: Behavioral Health Providers, Pharmacists and Prescribers N.C. Medicaid and N.C. Health Choice Preferred Drug List Changes - UPDATE
Attention: Behavioral Health Providers, Pharmacists and Prescribers N.C. Medicaid and N.C. Health Choice Drug List Changes - UPDATE Note: This article was previously published in the December 2014 Medicaid
Devon A. Sherwood, PharmD, BCPP Assistant Professor of Pharmacy Practice
Devon A. Sherwood, PharmD, BCPP Assistant Professor of Pharmacy Practice Differentiate dopamine neurotransmitter pathways associated with antipsychotic medications Identify therapy challenges associated
Medication Treatment of Cognitive and Behavioral Symptoms in Dementia
Medication Treatment of Cognitive and Behavioral Symptoms in Dementia Cary J. Kohlenberg, M.D. Medical Director, IPC Research and Independent Psychiatric Consultants Environmental interventions directly
2017 HEDIS Provider Guide and Toolkit
2017 HEDIS Provider Guide and Toolkit Prepared By: Quality Improvement Department, Molina Healthcare of Washington MolinaHealthcare.com HEDIS 2017 TABLE OF CONTENTS Welcome to 2017 HEDIS TIPS...3 Molina
New Patient Questionnaire
4 Embarcadero Center, Suite 1400, San Francisco, CA 94111 (415) 926-7774 phone; (415) 591-7760 office@sanfranciscopsych.com New Patient Questionnaire Thank you for trusting San Francisco Psychiatry with
Review of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)
Review of Psychotrophic Medications (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Common Psychiatric Disorders *Schizophrenia *Depression *Bipolar Disorder
**CRITERIA UNDER CMS REVIEW**
**CRITERIA UNDER CMS REVIEW** ANTICONVULSANTS APTIOM TABLET 200 MG APTIOM TABLET 400 MG APTIOM TABLET 600 MG APTIOM TABLET 800 MG BANZEL SUSPENSION 40 MG/ML BANZEL TABLET 200 MG BANZEL TABLET 400 MG BRIVIACT
Aripiprazole Lauroxil: Preparing for Commercial Success
Aripiprazole Lauroxil: Preparing for Commercial Success Mark Stejbach Chief Commercial Officer Alkermes R&D Day July 17, 2013 Forward-Looking Statements This presentation contains forward-looking statements
ARISTADA. Products Affected Step 2: ARISTADA PREFILLED SYRINGE 1064 MG/3.9ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 441 MG/1.
ARISTADA ARISTADA PREFILLED SYRINGE 1064 MG/3.9ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 441 MG/1.6ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 662 MG/2.4ML INTRAMUSCULAR ARISTADA PREFILLED SYRINGE 882